Dr. Mark A. Klein

Hematology Oncology
1 Veterans Dr, 111e Minneapolis Veterans Affairs Medical Center, 
Minneapolis, MN 
Clinical Trials:Currently Recruiting for 1 Trial
1 Veterans Dr, 111e Minneapolis Veterans Affairs Medical Center, 
Minneapolis, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Klein is a Hematologist Oncology provider in Minneapolis, Minnesota. His top areas of expertise are Pulmonary Embolism, Blood Clots, Primary Mediastinal B-Cell Lymphoma (PMBCL), and Small Lymphocytic Lymphoma (SLL).

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in MN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

1 Veterans Dr, 111e Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug
Study Drug: INC280
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
View 8 Less Clinical Trials

45 Total Publications

Treatment duration of immune checkpoint inhibitors and overall survival in U.S. veterans with Cancer.
Treatment duration of immune checkpoint inhibitors and overall survival in U.S. veterans with Cancer.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: July 11, 2025
Similar Doctors
Daniel J. Weisdorf
Expertise in
12
conditions
Dr. Daniel J. Weisdorf
Hematology Oncology | Hematology
Expertise in
12
conditions
Dr. Daniel J. Weisdorf
Hematology Oncology | Hematology
516 Delaware Street Se, Strpwb Fifth Floor, Suite 5-100, Clinic 5b, 
Minneapolis, MN 
 (5.1 miles away)
612-626-2663
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Weisdorf is a Hematologist Oncology specialist and a Hematologist in Minneapolis, Minnesota. Dr. Weisdorf is highly rated in 12 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Graft. Dr. Weisdorf is currently accepting new patients.

Expertise in
30
conditions
Dr. Mark T. Reding
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. Mark T. Reding
Hematology Oncology | Hematology | Oncology

Fairview Express Care

500 Harvard St Se, 
Minneapolis, MN 
 (5.0 miles away)
763-525-1746
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Reding is a Hematologist Oncology specialist and a Hematologist in Minneapolis, Minnesota. Dr. Reding is highly rated in 30 conditions, according to our data. His top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, Splenectomy, and Bone Marrow Transplant. Dr. Reding is currently accepting new patients.

Expertise in
25
conditions
Dr. Gregory M. Vercellotti
Hematology Oncology | Hematology | Oncology
Expertise in
25
conditions
Dr. Gregory M. Vercellotti
Hematology Oncology | Hematology | Oncology

Fairview Express Care

500 Harvard St Se, 
Minneapolis, MN 
 (5.0 miles away)
763-525-1746
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Vercellotti is a Hematologist Oncology specialist and a Hematologist in Minneapolis, Minnesota. Dr. Vercellotti is highly rated in 25 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vercellotti is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Klein's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile